Cargando…

Severe Asthma Remissions Induced by Biologics Targeting IL5/IL5r: Results from a Multicenter Real-Life Study

Add-on biological therapy has proven to be effective in many patients with severe eosinophilic asthma. In this observational multicenter retrospective study, we report the results obtained with mepolizumab and benralizumab in severe asthmatics treated for 12 months in a real-life setting. In these p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maglio, Angelantonio, Vitale, Carolina, Pelaia, Corrado, D’Amato, Maria, Ciampo, Luigi, Sferra, Eliana, Molino, Antonio, Pelaia, Giulia, Vatrella, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916787/ https://www.ncbi.nlm.nih.gov/pubmed/36768778 http://dx.doi.org/10.3390/ijms24032455

Ejemplares similares

Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life Setting
por: Vitale, Carolina, et al.
Publicado: (2023)

Eosinophilic inflammation: An Appealing Target for Pharmacologic Treatments in Severe Asthma
por: Vatrella, Alessandro, et al.
Publicado: (2022)

Real-Life Effectiveness of Mepolizumab on Forced Expiratory Flow between 25% and 75% of Forced Vital Capacity in Patients with Severe Eosinophilic Asthma
por: Maglio, Angelantonio, et al.
Publicado: (2021)

Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma
por: Pelaia, Corrado, et al.
Publicado: (2021)

Pathobiology of Type 2 Inflammation in Asthma and Nasal Polyposis
por: Pelaia, Corrado, et al.
Publicado: (2023)

Interleukins 4 and 13 in Asthma: Key Pathophysiologic Cytokines and Druggable Molecular Targets
por: Pelaia, Corrado, et al.
Publicado: (2022)

Novel Biological Therapies for Severe Asthma Endotypes
por: Pelaia, Corrado, et al.
Publicado: (2022)

Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13
por: Pelaia, Corrado, et al.
Publicado: (2022)

Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
por: Pelaia, Corrado, et al.
Publicado: (2017)

Benralizumab in the treatment of severe asthma: design, development and potential place in therapy
por: Pelaia, Corrado, et al.
Publicado: (2018)

Post-COVID-19 Patients Who Develop Lung Fibrotic-like Changes Have Lower Circulating Levels of IFN-β but Higher Levels of IL-1α and TGF-β
por: Colarusso, Chiara, et al.
Publicado: (2021)

Molecular Targets for Biological Therapies of Severe Asthma
por: Pelaia, Corrado, et al.
Publicado: (2020)

Clinical and Functional Effects of Inhaled Dual Therapy Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease: A Real-Life Study
por: Pelaia, Corrado, et al.
Publicado: (2023)

Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience
por: Scioscia, Giulia, et al.
Publicado: (2023)

Monoclonal Antibodies Targeting Alarmins: A New Perspective for Biological Therapies of Severe Asthma
por: Pelaia, Corrado, et al.
Publicado: (2021)

Interleukin-5 in the Pathophysiology of Severe Asthma
por: Pelaia, Corrado, et al.
Publicado: (2019)

Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness
por: Pelaia, Corrado, et al.
Publicado: (2018)

Activation of the AIM2 Receptor in Circulating Cells of Post-COVID-19 Patients With Signs of Lung Fibrosis Is Associated With the Release of IL-1α, IFN-α and TGF-β
por: Colarusso, Chiara, et al.
Publicado: (2022)

Role of p38 Mitogen-Activated Protein Kinase in Asthma and COPD: Pathogenic Aspects and Potential Targeted Therapies
por: Pelaia, Corrado, et al.
Publicado: (2021)

Targeting IL-4 and IL-13 Receptors on Eosinophils in CRSwNP Patients: The Clinical Efficacy of Dupilumab
por: Piazzetta, Giovanna Lucia, et al.
Publicado: (2023)

Short-Term Evaluation of Dupilumab Effects in Patients with Severe Asthma and Nasal Polyposis
por: Pelaia, Corrado, et al.
Publicado: (2021)

Asthma-related deaths
por: D’Amato, Gennaro, et al.
Publicado: (2016)

Benralizumab Effectiveness in Severe Eosinophilic Asthma with Co-Presence of Bronchiectasis: A Real-World Multicentre Observational Study
por: Campisi, Raffaele, et al.
Publicado: (2023)

Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma
por: Pelaia, Corrado, et al.
Publicado: (2018)

Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps
por: Pelaia, Corrado, et al.
Publicado: (2023)

Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a review
por: D’Amato, Gennaro, et al.
Publicado: (2014)

Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study
por: Nolasco, Santi, et al.
Publicado: (2023)

Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression
por: Pelaia, Corrado, et al.
Publicado: (2021)

Effects on asthma and respiratory allergy of Climate change and air pollution
por: D’Amato, Gennaro, et al.
Publicado: (2015)

Special Issue on ‘Asthma and Allergic Inflammation’
por: Pelaia, Corrado
Publicado: (2023)

Lung under attack by COVID-19-induced cytokine storm: pathogenic mechanisms and therapeutic implications
por: Pelaia, Corrado, et al.
Publicado: (2020)

Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence
por: Pelaia, Corrado, et al.
Publicado: (2021)

Effects of the first three doses of benralizumab on symptom control, lung function, blood eosinophils, oral corticosteroid intake, and nasal polyps in a patient with severe allergic asthma
por: Pelaia, Corrado, et al.
Publicado: (2020)

Dupilumab: a novel treatment for asthma
por: Vatrella, Alessandro, et al.
Publicado: (2014)

Spotlight on a Short-Time Treatment with the IL-4/IL-13 Receptor Blocker in Patients with CRSwNP: microRNAs Modulations and Preliminary Clinical Evidence
por: Mimmi, Selena, et al.
Publicado: (2022)

Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
por: Carpagnano, Giovanna Elisiana, et al.
Publicado: (2021)

Update on Anticytokine Treatment for Asthma
por: Gallelli, Luca, et al.
Publicado: (2013)

Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub‐phenotypes of response identified by cluster analysis
por: Di Bona, Danilo, et al.
Publicado: (2021)

Biologicals decrease psychological distress, anxiety and depression in severe asthma, despite Covid-19 pandemic
por: Patella, Vincenzo, et al.
Publicado: (2022)

Diagnostic yield and safety of C-TBNA in elderly patients with lung cancer
por: Vitale, Carolina, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_u8hjg30no1rsjhl6d499mb1p16